Most cited papers from Aichi Cancer Center

Aichi Cancer Center

What are the most cited papers from Aichi Cancer Center?

The most cited paper from Aichi Cancer Center is "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial" (Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al., 2010), with 7,405 citations. Next come "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer" (5,138) and "International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma" (4,890).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 780 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial Yung‐Jue Bang, Eric Van Cutsem, Andrea Feyereislova et al. · The Lancet Open access	Aug 2010	7,405
2	Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer Martine J Piccart et al. · New England Journal of Medicine Open access	20 Oct 2005	5,138
3	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma William David Travis et al. · Journal of Thoracic Oncology Open access	20 Jan 2011	4,890
4	Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Achim Rittmeyer et al. · The Lancet Open access	12 Dec 2016	4,817
5	The 2015 World Health Organization Classification of Lung Tumors William David Travis, Elisabeth M. Brambilla, Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology Open access	21 Aug 2015	4,651
6	MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science	26 Apr 2007	4,504
7	Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine Open access	20 Oct 2018	4,469
8	Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Tetsuya Mitsudomi et al. · The Lancet Oncology	19 Dec 2009	4,130
9	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer Eric Van Cutsem et al. · Annals of Oncology Open access	5 Jul 2016	3,512
10	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia Courtney Denton Dinardo et al. · New England Journal of Medicine Open access	12 Aug 2020	2,918
11	Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer Fabrice André, Eva M. Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine Open access	15 May 2019	2,660
12	Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine Shinichi Sakuramoto, Mitsuru Sasako, Toshiharu Yamaguchi et al. · New England Journal of Medicine Open access	31 Oct 2007	2,547
13	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hansjochen Wilke, Kei Muro, Eric Van Cutsem et al. · The Lancet Oncology	17 Sep 2014	2,505
14	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer Japanese Society for Cancer of the Colon and Rectum et al. · International Journal of Clinical Oncology Open access	27 Mar 2017	2,496
15	Comprehensive genomic profiles of small cell lung cancer Julie George et al. · Nature Open access	10 Jul 2015	2,448
16	Reduced Expression of the let-7 MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival Junichi Takamizawa, Hiroyuki Konishi, Kiyoshi Yanagisawa et al. · Cancer Research	Jun 2004	2,373
17	International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas Masao Tanaka, Carlos Fernández-del Castillo, Volkan N. Adsay et al. · Pancreatology	May 2012	2,359
18	Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Yoon‐Koo Kang et al. · The Lancet Open access	12 Oct 2017	2,317
19	International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas Masao Tanaka, Suresh T. Chari, Volkan N. Adsay et al. · Pancreatology	30 Nov 2005	2,051
20	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer Shanu Modi et al. · New England Journal of Medicine Open access	11 Dec 2019	2,026
21	Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer Yojiro Hashiguchi et al. · International Journal of Clinical Oncology Open access	15 Jun 2019	2,012
22	Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy Norikazu Masuda et al. · New England Journal of Medicine Open access	31 May 2017	1,947
23	S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial Wasaburo Koizumi, Hiroyuki Narahara, Takuo Hara et al. · The Lancet Oncology	22 Feb 2008	1,876
24	Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology Open access	2 Mar 2016	1,870
25	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial Javier Cortés et al. · The Lancet Open access227 authors	Dec 2020	1,856
26	Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Charles S. Fuchs et al. · JAMA Oncology Open access	15 Mar 2018	1,835
27	Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas Masao Tanaka, Carlos Fernández‐del Castillo, Terumi Kamisawa et al. · Pancreatology	13 Jul 2017	1,816
28	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes Rainer Malik et al. · Nature Genetics Open access428 authors	12 Mar 2018	1,753
29	Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer Nicholas C. Turner, Jungsil Ro, Fabrice André et al. · New England Journal of Medicine Open access	Jun 2015	1,606
30	Association analysis identifies 65 new breast cancer risk loci Kyriaki Michailidou et al. · Nature Open access362 authors	20 Oct 2017	1,602
31	A Polycistronic MicroRNA Cluster, miR-17-92 , Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation Yoji Hayashita, Hirotaka Osada, Yoshio Tatematsu et al. · Cancer Research	Nov 2005	1,524
32	A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki et al. · Annals of Surgical Oncology Open access	30 Aug 2011	1,459
33	Coronavirus disease 2019 (COVID-19): A literature review Harapan Harapan, Naoya Itoh, Amanda Yufika et al. · Journal of Infection and Public Health Open access	8 Apr 2020	1,451
34	Irinotecan plus Cisplatin Compared with Etoposide plus Cisplatin for Extensive Small-Cell Lung Cancer Kazumasa Noda, Yutaka Nishiwaki, Masaaki Kawahara et al. · New England Journal of Medicine Open access	10 Jan 2002	1,376
35	Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Kohei Shitara et al. · The Lancet Open access158 authors	4 Jun 2018	1,338
36	Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine Open access	20 Oct 2018	1,321
37	Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial Ken Kato, Byoung Chul Cho, Masanobu Takahashi et al. · The Lancet Oncology Open access	30 Sep 2019	1,262
38	Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh et al. · Cancer Research	15 Dec 2004	1,237
39	Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial Peter Schmid, Hope S. Rugo, Sylvia Adams et al. · The Lancet Oncology	27 Nov 2019	1,226
40	Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer Takashi Kojima et al. · Journal of Clinical Oncology	7 Oct 2020	1,199
41	Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer Javier Cortés, Hope S. Rugo, David W. Cescon et al. · New England Journal of Medicine Open access	20 Jul 2022	1,193
42	EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors Young Lim Choi, Manabu Soda, Yoshihiro Yamashita et al. · New England Journal of Medicine Open access	27 Oct 2010	1,192
43	Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01) Katsuhiko Uesaka, Narikazu Boku, Akira Fukutomi et al. · The Lancet	3 Jun 2016	1,145
44	Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial Kei Muro, Hyun Cheol Chung, Veena Shankaran et al. · The Lancet Oncology Open access	3 May 2016	1,137
45	Large-scale genotyping identifies 41 new loci associated with breast cancer risk Kyriaki Michailidou et al. · Nature Genetics Open access222 authors	27 Mar 2013	1,109
46	Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial Elizabeth Ann Mittendorf, Hong Zhang, Carlos H. Barrios et al. · The Lancet Open access	20 Sep 2020	1,099
47	Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability–High/Mismatch Repair–Deficient Metastatic Colorectal Cancer: KEYNOTE-164 Dung Thi Le et al. · Journal of Clinical Oncology Open access	14 Nov 2019	1,038
48	Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Jürgen Wolf et al. · New England Journal of Medicine Open access	2 Sep 2020	1,029
49	D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer Mitsuru Sasako, Takeshi Sano, Seiichiro Yamamoto et al. · New England Journal of Medicine Open access	30 Jul 2008	1,029
50	Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh et al. · Journal of Clinical Oncology	Mar 2005	960

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.